| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Merck & Company Inc. | ACE-083 | Charcot-Marie-Tooth disease (CMT) | Phase 2 | Intramuscular | Neurology | |
| Merck & Company Inc. | Ensifentrine (RPL554) | COPD | Phase 2 | Trial Discontinued | Inhalation | Respiratory |
| Merck & Company Inc. | Tulisokibart (PRA023) - (APOLLO-CD) | Crohn’s Disease | Phase 2a | Data Released | Intravenous | Gastroenterology |
| Mereo BioPharma Group plc | Acumapimod | Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AECOPD) | Phase 3 | Trial Planned | Oral | Respiratory |
| Mereo BioPharma Group plc | Acumapimod | Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AECOPD) | Phase 3 | Trial Planned | Oral | Respiratory |
| Mereo BioPharma Group plc | Setrusumab - (Cosmic) | Osteogenesis imperfecta (OI) | Phase 3 | Data Released | Intravenous | Genetic Disorder |
| Mereo BioPharma Group plc | Setrusumab (BPS-804) - (ORBIT) | Osteogenesis Imperfecta | Phase 2/3 | Data Released | Intravenous | Orthopedic |
| Mereo BioPharma Group plc | Vantictumab (OMP18R5) | Autosomal dominant osteopetrosis Type 2 (ADO2) | Phase 2 | Trial Planned | Intravenous | Genetic Disorder |